Globe NewsWire News Distribution Service

Details

Written by Globe NewsWire Press Releases

Category: Globe NewsWire News Distribution Service

Published: 06 April 2025

Created: 06 April 2025

Last Updated: 06 April 2025

BOSTON, April 06, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the Company will hold a conference call and webcast on Monday, April 7, 2025 at 8:00 a.m. ET to disclose topline results from the…

Posted: 2025-04-06 16:00:00

Get Full News Story On GlobeNewsWire Press Release Service

Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.

• Prev
• Next

Related Bing News Search Results

Press Release: Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with Acquired Hypothalamic Obesity - Newscast

Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update

Wed, 07 May 2025 04:26:00 GMT Rhythm Pharmaceuticals will host a live conference call and webcast at 8:00 a.m. ET today to review its first quarter 2025 financial results and recent business activities. Participants may register ...

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue Estimates

Wed, 07 May 2025 01:09:00 GMT Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $2.35 per share a year ago.

Rhythm Pharmaceuticals, Inc. (RYTM)

Tue, 06 May 2025 17:00:00 GMT While not GlobeNewswire • 14 days ago Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120 ...

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

Tue, 06 May 2025 05:11:00 GMT To report SUSPECTED ADVERSE REACTIONS, contact Rhythm Pharmaceuticals at +1 (833) 789-6337 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. See section 4.8 of the Summary of Product Characteristics ...